Triumph Capital Management’s AstraZeneca AZN Stock Holding History

Triumph Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36K	Sell	190 -2	-1%	-$376	0.01%	767
2026 Q1	$37.9K	Sell	192 -23	-11%	-$4.43K	0.01%	712
2025 Q4	$39.5K	Buy	+215	New	+$37.7K	0.01%	668
2024 Q1	–	Sell	-1,728	Closed	-$233K	–	227
2023 Q4	$233K	Buy	1,728 +136	+9%	+$17.7K	0.1%	182
2023 Q3	$216K	Buy	+1,592	New	+$217K	0.1%	193

Other funds holding AZN

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return

ZIC

ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return

AIM

Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return

CAM

Cidel Asset Management Toronto, Ontario, Ontario, Canada $2.08B AUM 24.89% 1-Year Est. Return

MBI

Montrusco Bolton Investments Montreal, Quebec, Canada $6.46B AUM 26.7% 1-Year Est. Return

SAM

Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return

Triumph Capital Management's AZN Position: Q2 2026 in Review

Triumph Capital Management reduced its AstraZeneca (AZN) stake by 1% in Q2 2026, selling an estimated $376 and leaving 190 shares worth $36K. The position accounts for 0.01% of the portfolio, ranked #767.

Triumph Capital Management first reported a position in AZN in Q3 2023 and has held it in 5 quarters since. The position peaked at $233K in Q4 2023. 351 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Triumph Capital Management held 190 shares of AstraZeneca worth $36K as of Q2 2026.
Triumph Capital Management sold 2 AstraZeneca shares in Q2 2026, an estimated $376.
AstraZeneca made up 0.01% of Triumph Capital Management's portfolio in Q2 2026, its #767 holding.
Triumph Capital Management first reported a position in AstraZeneca in Q3 2023 and has held it in 5 quarters since.
Triumph Capital Management's AstraZeneca position peaked at $233K in Q4 2023.
351 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.